Ardent Health (ARDT) EBITDA (2023 - 2026)

Ardent Health has reported EBITDA for 4 years, with the latest figure at -$90.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 60.09% year-over-year to -$90.6 million; the trailing twelve-month figure through Mar 2026 stood at -$518.3 million (up 21.62% YoY), and the FY2025 full-year result was -$796.6 million, down 18.88% from the prior year.
• EBITDA for Q1 2026 stood at -$90.6 million, up from -$185.2 million in the prior quarter.
• The five-year high for EBITDA was $300.8 million in Q4 2023, with the low at -$511.0 million in Q4 2024.
• Average EBITDA over 4 years is -$100.0 million, with a median of -$69.7 million recorded in 2023.
• Year-over-year, EBITDA plunged 269.89% in 2024 and soared 71.89% in 2025.
• Tracing ARDT's EBITDA over 4 years: stood at $300.8 million in 2023, then sank by 269.89% to -$511.0 million in 2024, then jumped by 63.77% to -$185.2 million in 2025, then jumped by 51.09% to -$90.6 million in 2026.
• The last three EBITDA figures came in at -$90.6 million (Q1 2026), -$185.2 million (Q4 2025), and -$200.9 million (Q3 2025), per Business Quant data.

Peer Comparison